Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study

Sijian Yu, Qifa Liu, Yu Zhang, Guopan Yu, Yu Wang, Ruoyang Shao, Qiong Liu

Blood (2023) 142 (Supplement 1): 1530.

https://doi.org/10.1182/blood-2023-182638

Published: 2023

Journal Articles

Prophylactic or Preemptive Donor-Derived CD19 CAR-T Cell Infusion for Preventing Relapse in High-Risk B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 2100.

https://doi.org/10.1182/blood-2023-173926

Published: 2023

Journal Articles

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

Guopan Yu, Zhao Yin, Zurong Yao, Xiaqi Nie, Hua Jin, Yu Zhang, Dan Xu, Xuejie Jiang, Baohong Ping

Blood (2023) 142 (Supplement 1): 6038.

https://doi.org/10.1182/blood-2023-182668

Published: 2023

Journal Articles

Clinical Implications of CSF-Ctdna in CNS Involvement of Newly Diagnosed Diffuse Large B Cell Lymphoma: An Improvement of Diagnosis, Treatment and Evaluation

Jinhua Liang, Yi-fan Wu, Hao-Rui Shen, Yue Li, Jun-heng Liang, Xin-Yu Zhang, Sibusiso Luthuli, Jiazhu Wu, Liu qing Zhu, Hua Yin, Li Wang, Jianyong Li, Xu Wei

Blood (2023) 142 (Supplement 1): 188.

https://doi.org/10.1182/blood-2023-181666

Published: 2023

Journal Articles

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Guopan Yu, Yu Zhang, Hua Jin, Zhao Yin, Guangyang Weng, Sijian Yu, Na Xu, Xin Du, Dongjun Lin, Jie Xiao, Zhiqiang Sun, Hongyu Zhang, Xinquan Liang, Ziwen Guo, Weihua Zhao, Min Dai, Xuejie Jiang, Li Xuan, Pengcheng Shi

Blood (2023) 142 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2023-182847

Published: 2023

Journal Articles

A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults

Blood (2023) 142 (Supplement 1): 2106.

https://doi.org/10.1182/blood-2023-180387

Published: 2023

Journal Articles

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Blood (2023) 142 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2023-184959

Published: 2023

Journal Articles

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

Guopan Yu, Zhao Yin, Jixian Huang, Huiqing He, Xuejie Jiang, Hongsheng Zhou, Pengcheng Huang, Yu Zhang

Blood (2023) 142 (Supplement 1): 5862.

https://doi.org/10.1182/blood-2023-182621

Published: 2023

Journal Articles

Efficacy and Safety of Avatrombopag in the Treatment of Chemotherapy-Induced Thrombocytopenia Refractory to Rhtpo in Patients with Lymphoma

Xu Wei, Hao-Rui Shen, Xin-Yu Zhang, Jiazhu Wu, Hua Yin, Yue Li, Jinhua Liang, Li Wang

Blood (2023) 142 (Supplement 1): 5452.

https://doi.org/10.1182/blood-2023-184420

Published: 2023

Journal Articles

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu, Zhao Yin, Yu Zhang, Xuejie Jiang, Xiaqi Nie, Zurong Yao, Dan Xu, Pengcheng Shi

Blood (2023) 142 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2023-184772

Published: 2023

Journal Articles

Rapid Etiological Detection Value of Metagenomic Next-Generation Sequencing for Bloodstream Infections in Patients with High-Risk Hematologic Malignancies

Hong Qu, Yu Zhang, Na Xu, Shuqin Cheng

Blood (2022) 140 (Supplement 1): 3231–3232.

https://doi.org/10.1182/blood-2022-162289

Published: 2022

Journal Articles

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Dan Xu, Ying Yang, Zhao Yin, Sanfang Tu, Danian Nie, Qixin Sun, Zhengqian Huang, Yu Zhang, Guopan Yu

Blood (2022) 140 (Supplement 1): 9097.

https://doi.org/10.1182/blood-2022-159589

Published: 2022

Journal Articles

Identification of Pyroptosis-Related Signature and Development of a Novel Prognostic Model in Diffuse Large B-Cell Lymphoma

Liemei Lv, Yu Zhang, Yiqing Cai, Zhuoya Yu, Xueling Ge, Xiaosheng Fang, Cong Wang, Ran Kong, Xin Wang, Xiangxiang Zhou

Blood (2022) 140 (Supplement 1): 3589–3590.

https://doi.org/10.1182/blood-2022-162939

Published: 2022

Journal Articles

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Guopan Yu, Zhao Yin, Dan Xu, Xuejie Jiang, Jieyu Ye, Yu Zhang

Blood (2022) 140 (Supplement 1): 11740.

https://doi.org/10.1182/blood-2022-169333

Published: 2022

Journal Articles

Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial

Pengcheng Shi, Xi Jia, Naying Liao, Yin Changxin, Huan Li, Xuejie Jiang, Guopan Yu, Jieyu Ye, Hong Qu, Yu Zhan, Chunju Wen, Yu Zhang, Qifa Liu

Blood (2022) 140 (Supplement 1): 2005–2006.

https://doi.org/10.1182/blood-2022-156348

Published: 2022

Journal Articles

Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies

Yu Zhang, Ying Wang, Runxia Gu, Lin Shi, Yongzeng Wang, Yi Feng, Lulu Lv, Qing Rao, Min Wang, Jianxiang Wang

Blood (2022) 140 (Supplement 1): 630–631.

https://doi.org/10.1182/blood-2022-162345

Published: 2022

Journal Articles

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2022-158688

Published: 2022

Journal Articles

Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu, Zhao Yin, Hua Jin, Sijian Yu, Yuhua Li, Danian Nie, Ziwen Guo, Zhiqiang Sun, Qingxiang Meng, Weihua Zhao, Dongjun Lin, Na Xu, Yu Zhang

Blood (2022) 140 (Supplement 1): 11796.

https://doi.org/10.1182/blood-2022-168004

Published: 2022

Journal Articles

A Novel NGS Assay to Detect Any KMT2A fusion Transcript at Low Levels

Ghayas C. Issa, Aram Bidikian, Hannah Roberts, Wenjun Li, Cailin Weller, Rafita Alam, Paola Gonzalez, Blair Maupin, Kaitlyn Nguyen, Edaena Guzman, Evelynn Nguyen, Laura Casas Lumbreras, Deepak Thirunavukarasu, Alessandro Pinto, David Yu Zhang

Blood (2022) 140 (Supplement 1): 10738–10740.

https://doi.org/10.1182/blood-2022-164890

Published: 2022

Journal Articles

Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Guangyang Weng, Yu Zhang, Guopan Yu, Na Xu, Zhiqiang Sun, Dongjun Lin, Xinquan Liang, Lan Deng, Jie Xiao, Hongyu Zhang, Ziwen Guo, Hua Jin, Xin Du, Qifa Liu

Blood (2022) 140 (Supplement 1): 2025–2026.

https://doi.org/10.1182/blood-2022-158762

Published: 2022

NARROW

Sorafenib Plus Triplet Therapy with Venetoclax, Azacitibine and Homoharringtonine for Refractory/Relapsed Acute Myeloid Leukemia with FLT3-ITD: A Multicentre, Phase 2 Study

Prophylactic or Preemptive Donor-Derived CD19 CAR-T Cell Infusion for Preventing Relapse in High-Risk B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

Clinical Implications of CSF-Ctdna in CNS Involvement of Newly Diagnosed Diffuse Large B Cell Lymphoma: An Improvement of Diagnosis, Treatment and Evaluation

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

Efficacy and Safety of Avatrombopag in the Treatment of Chemotherapy-Induced Thrombocytopenia Refractory to Rhtpo in Patients with Lymphoma

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Rapid Etiological Detection Value of Metagenomic Next-Generation Sequencing for Bloodstream Infections in Patients with High-Risk Hematologic Malignancies

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Identification of Pyroptosis-Related Signature and Development of a Novel Prognostic Model in Diffuse Large B-Cell Lymphoma

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial

Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Influence of Molecular Abnormalities on Treatment Response of Venetoclax Plus Azacytidine and Homoharringtonine Versus Venetoclax Plus Hypomethylating Agent in Relapsed/Refractory Acute Myeloid Leukemia

A Novel NGS Assay to Detect Any KMT2A fusion Transcript at Low Levels

Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only